BMJ 2001;323:131 ( 21 July )

Papers

Third generation oral contraceptives and risk of venous thrombosis: meta-analysis

Jeanet M Kemmeren, research fellow,  Ale Algra, associate professor of clinical epidemiology,  Diederick E Grobbee, professor of clinical epidemiology. 

Julius Centre for General Practice and Patient Oriented Research, University Medical Centre Utrecht, PO Box 85500, 3508 GA Utrecht, Netherlands

Correspondence to: A Algra A.Algra{at}neuro.azu.nl

Objective: To evaluate quantitatively articles that compared effects of second and third generation oral contraceptives on risk of venous thrombosis.
Design: Meta-analysis.
Studies: Cohort and case-control studies assessing risk of venous thromboembolism among women using oral contraceptives before October 1995.
Main outcome measures: Pooled adjusted odds ratios calculated by a general variance based random effects method. When possible, two by two tables were extracted and combined by the Mantel-Haenszel method.
Results: The overall adjusted odds ratio for third versus second generation oral contraceptives was 1.7 (95% confidence interval 1.4 to 2.0; seven studies). Similar risks were found when oral contraceptives containing desogestrel or gestodene were compared with those containing levonorgestrel. Among first time users, the odds ratio for third versus second generation preparations was 3.1 (2.0 to 4.6; four studies). The odds ratio was 2.5 (1.6 to 4.1; five studies) for short term users compared with 2.0 (1.4 to 2.7; five studies) for longer term users. The odds ratio was 1.3 (1.0 to 1.7) in studies funded by the pharmaceutical industry and 2.3 (1.7 to 3.2) in other studies. Differences in age and certainty of diagnosis of venous thrombosis did not affect the results.
Conclusions: This meta-analysis supports the view that third generation oral contraceptives are associated with an increased risk of venous thrombosis compared with second generation oral contraceptives. The increase cannot be explained by several potential biases.

What is already known on this topic Third generation oral contraceptives have been reported to increase the risk of venous thrombosis compared with second generation oral contraceptives The findings have been vigorously debated, with suggestions that the results can be explained by confounding or bias, or both. What this study adds Women taking third generation oral contraceptives have a 1.7-fold increased risk of venous thrombosis compared with those taking second generation oral contraceptives Risk is highest in first time users The biases were not large enough to account for the observed results

---

© BMJ 2001
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Increased risk of thrombosis with third generation oral contraceptives is real
BMJ 2001 323: 0. [Full Text]

The third generation pill controversy ("continued")

J O Drife
BMJ 2001 323: 119-120. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Rathbun, S. (2008). Venous thromboembolism in women. Vasc Med 13: 255-266 [Abstract]  
• (2008). Contraception in Women with Medical Problems. JWatch Women's Health 2008: 2-2 [Full text]  
• Vieira, C.S., Ferriani, R.A., Garcia, A.A., Pintao, M.C., Azevedo, G.D., Gomes, M.K.O., Silva-de-Sa, M.F. (2007). Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. Hum Reprod 22: 2196-2201 [Abstract] [Full text]  
• Sitruk-Ware, R., Plu-Bureau, G., Menard, J., Conard, J., Kumar, S., Thalabard, J.-C., Tokay, B., Bouchard, P. (2007). Effects of Oral and Transvaginal Ethinyl Estradiol on Hemostatic Factors and Hepatic Proteins in a Randomized, Crossover Study. J. Clin. Endocrinol. Metab. 92: 2074-2079 [Abstract] [Full text]  
• Pezzini, A, Grassi, M, Iacoviello, L, Del Zotto, E, Archetti, S, Giossi, A, Padovani, A (2007). Inherited thrombophilia and stratification of ischaemic stroke risk among users of oral contraceptives. J. Neurol. Neurosurg. Psychiatry 78: 271-276 [Abstract] [Full text]  
• Smith, N. L., Heckbert, S. R., Lemaitre, R. N., Reiner, A. P., Lumley, T., Rosendaal, F. R., Psaty, B. M. (2006). Conjugated Equine Estrogen, Esterified Estrogen, Prothrombotic Variants, and the Risk of Venous Thrombosis in Postmenopausal Women. Arterioscler. Thromb. Vasc. Bio. 26: 2807-2812 [Abstract] [Full text]  
• The ESHRE Capri Workshop Group, (2006). Hormones and cardiovascular health in women. Hum Reprod Update 12: 483-497 [Abstract] [Full text]  
• Sitruk-Ware, R. (2006). New progestagens for contraceptive use. Hum Reprod Update 12: 169-178 [Abstract] [Full text]  
• van Asselt, K. M., Kok, H. S., van der Schouw, Y. T., Peeters, P. H.M., Pearson, P. L., Grobbee, D. E. (2006). Role of Genetic Analyses in Cardiology: Part II: Heritability Estimation for Gene Searching in Multifactorial Diseases. Circulation 113: 1136-1139 [Full text]  
• Baillargeon, J.-P., McClish, D. K., Essah, P. A., Nestler, J. E. (2005). Association between the Current Use of Low-Dose Oral Contraceptives and Cardiovascular Arterial Disease: A Meta-Analysis. J. Clin. Endocrinol. Metab. 90: 3863-3870 [Abstract] [Full text]  
• Decensi, A., Maisonneuve, P., Rotmensz, N., Bettega, D., Costa, A., Sacchini, V., Salvioni, A., Travaglini, R., Oliviero, P., D'Aiuto, G., Gulisano, M., Gucciardo, G., del Turco, M. R., Pizzichetta, M. A., Conforti, S., Bonanni, B., Boyle, P., Veronesi, U., for the Italian Tamoxifen Study Group, (2005). Effect of Tamoxifen on Venous Thromboembolic Events in a Breast Cancer Prevention Trial. Circulation 111: 650-656 [Abstract] [Full text]  
• van Vliet, H. A.A.M., Frolich, M., Christella, M., Thomassen, L.G.D., Doggen, C. J.M., Rosendaal, F. R., Rosing, J., Helmerhorst, F. M. (2005). Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod 20: 563-568 [Abstract] [Full text]  
• Rosendaal, F. R. (2005). Venous Thrombosis: The Role of Genes, Environment, and Behavior. ASH Education Book 2005: 1-12 [Abstract] [Full text]  
• Gomes, M. P. V., Deitcher, S. R. (2004). Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy: A Clinical Review. Arch Intern Med 164: 1965-1976 [Abstract] [Full text]  
• Petitti, D. B. (2003). Combination Estrogen-Progestin Oral Contraceptives. NEJM 349: 1443-1450 [Full text]  
• (2003). British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 58: 470-483 [Full text]  
• Lexchin, J., Bero, L. A, Djulbegovic, B., Clark, O. (2003). Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326: 1167-1170 [Abstract] [Full text]  
• Tanis, B.C (2003). Oral contraceptives and the risk of myocardial infarction. Eur Heart J 24: 377-380 [Full text]  
• Wooltorton, E. (2003). Diane-35 (cyproterone acetate): safety concerns. CMAJ 168: 455-456 [Full text]  
• de Jong-van den Berg, L., Tobi, H., Bijker, B., van den Berg, P. (2003). Influence of the third generation pill controversy on prescriptions for oral contraceptives among first time users: population based study. BMJ 326: 254-254 [Full text]  
• Seibert, C., Barbouche, E., Fagan, J., Myint, E., Wetterneck, T., Wittemyer, M. (2003). Prescribing Oral Contraceptives for Women Older Than 35 Years of Age. ANN INTERN MED 138: 54-64 [Abstract] [Full text]  
• Hoetzer, G. L., Stauffer, B. L., Greiner, J. J., Casas, Y., Smith, D. T., DeSouza, C. A. (2003). Influence of oral contraceptive use on endothelial t-PA release in healthy premenopausal women. Am. J. Physiol. Endocrinol. Metab. 284: E90-E95 [Abstract] [Full text]  
• Skegg, D. C G (2002). Oral contraceptives, venous thromboembolism, and the courts. BMJ 325: 504-505 [Full text]  
• Vandenbroucke, J. P. (2002). Alternative treatments in reproductive medicine: The vexing problem of `seemingly impeccable trials....'. Hum Reprod 17: 2228-2229 [Abstract] [Full text]  
• (2002). Western medicine: a confidence trick driven by the drug industry?. BMJ 325: 0-0 [Full text]  
• Hannaford, P., Vandenbroucke, J. P., Kahlenborn, C., Li, S. F., Shapiro, S., Rosendaal, F. R., Tanis, B. C., van der Graaf, Y., Chasan-Taber, L., Stampfer, M. J. (2002). Oral Contraceptives and the Risk of Myocardial Infarction. NEJM 346: 1826-1829 [Full text]  
• Bauer, K. A. (2002). Hormone Replacement Therapy and the Factor V Leiden Mutation. Arterioscler. Thromb. Vasc. Bio. 22: 879-880 [Full text]  
• Rosendaal, F.R., Helmerhorst, F.M., Vandenbroucke, J.P. (2002). Female Hormones and Thrombosis. Arterioscler. Thromb. Vasc. Bio. 22: 201-210 [Abstract] [Full text]  
• Bauer, K. A., Rosendaal, F. R., Heit, J. A. (2002). Hypercoagulability: Too Many Tests, Too Much Conflicting Data. ASH Education Book 2002: 353-368 [Abstract] [Full text]  
• (2001). Third-Generation Oral Contraceptives and VTE: A Reanalysis. JWatch General 2001: 4-4 [Full text]  
• Drife, J O (2001). The third generation pill controversy (""continued""). BMJ 323: 119-120 [Full text]  

Rapid Responses:

Read all Rapid Responses

Third generation oral contraceptives and risk of venous thromboembolism

Margaret Thorogood
bmj.com, 26 Jul 2001 [Full text]

Re: Third generation oral contraceptives and risk of venous thromboembolism

Jeanet M Kemmeren, et al.
bmj.com, 2 Mar 2002 [Full text]